Surprising Results From Emergency Contraceptive Access Study

In a recent study to see whether or not Emergency Contraceptives were easily and readily accessible based on the FDA guidelines, the study gave some very surprising results.

The study was concluded by researchers from Boston Medical Center (BMC) and Boston University School of Medicine (BUSM).  The results found that in low-income neighborhoods, misinformation about access to emergency contraception is a common occurrence.

What is Emergency Contraception?

Emergency contraception, or emergency birth control, is used to help keep a woman from getting pregnant after she has had sex without using birth control or if the birth control method failed.

In 2009, the U.S. Food and Drug Administration (FDA) approved Plan B One-Step and Next Choice, 2 very common Emergency Contraceptives, for sale without a prescription, thus available over-the-counter to those 17 and older. Women and men must show proof of age to buy either one.  If a person younger than 17 needs emergency contraception, they will need a prescription.

The Study

From September to December 2010, female research assistants posing as adolescents who recently had unprotected intercourse were randomly assigned to call every commercial pharmacy in Nashville, Tenn.; Philadelphia; Cleveland; Austin, Texas; and Portland, Ore. Cities were chosen in geographically diverse states without pharmacy access laws that supersede uniform federal regulations. Callers followed standardized scripts to simulate real-world calls and elicit specific information on emergency contraception availability and access.

Researchers then examined same-day availability of emergency contraception, (regardless of reason), whether emergency contraception could be accessed by the caller, and whether the pharmacy communicated the correct age at which emergency contraception was accessible over-the-counter.

Although the researchers found the availability of emergency contraception did not differ based on neighborhood income, in 19 percent of calls the adolescent was told she could not obtain emergency contraception under any circumstance. This misinformation occurred more often (23.7 percent compared to 14.6 percent) among pharmacies in low-income neighborhoods.

When callers queried the age threshold for over-the-counter access, they were given the correct age less often by pharmacies in low-income neighborhoods (50.0 percent compared to 62.8 percent). In all but 11 calls, the incorrect age was stated as erroneously too high, potentially restricting access.

“Even though we found approximately 80 percent same-day availability of emergency contraception in these metropolitan cities, misinformation regarding access was common-particularly in low-income neighborhoods,” said lead author Tracey Wilkinson, MD, MPH, a Fellow in the Division of General Pediatrics pediatrician at BMC/BUSM.

While the study design did not determine why disparities in access to emergency contraception exists, the researcher believes possible explanations include differences in pharmacy staffing or training, frequency of requests for information or organizational cultures around customer service. “Our study assessed only telephone calling and not in-person visits. Despite this limitation, the finding that misinformation regarding emergency contraception access is more common in neighborhoods with the highest teen pregnancy rates suggests that targeted consumer or provider education for consumers and pharmacy staff may be necessary,” she said. “We look forward to working with various companies, organizations and pharmacy staff to improve education regarding current regulations on emergency contraception access.”

These findings appear as a research letter in the Dec. 19 on-line issue of the Journal of the American Medical Association.



, , , , , ,

No comments yet.

Leave a Reply

GET HELP NOW!
  • This field is for validation purposes and should be left unchanged.
Latest Drug Injury News

Heightened Thrombosis Risk with Birth Control Patch and Ring

A BMJ study has found more evidence that women using the transdermal contraceptive patch or vaginal ring do indeed face higher thrombosis risks than those taking their contraceptive orally. Using Danish national registries, researchers studied over 1.5 million women without prior thrombotic disease or cancer, who were not pregnant. Overall, the incidence of venous thrombosis [...]

Is Your Heartburn Medication Putting You At Risk?

According to a new study, your heartburn medication could be putting you at risk for a nasty stomach bug! The infection, Clostridium difficile infection, also called C. difficile or CDI, is a hard-to-cure infection that causes severe diarrhea that has recently been linked to proton pump inhibitors (PPIs), the most powerful class of antacid drugs. [...]

Cipralex and Abnormal Heart Rhythms

Health Canada is informing Canadians of a labeling update for the prescription drug Cipralex (Escitalopram) regarding a dose-related risk of abnormal heart rhythms. The risk is dose-related, 20 mg per day is still the maximum recommended dose for most patients. Before starting Cipralex, talk to your healthcare professional. If you have had any heart problems, what other medications you [...]

Florida Compounding Pharmacy Linked To Rare Fungal Eye Infections

Whats that in my eye?! Thirty-three cases of a rare, but serious, fungal eye infection have been confirmed across seven states. Federal officials are announcing that the infection stemmed from products mixed in a Florida compounding pharmacy. it seems the victims underwent some sort of an eye procedure, either a surgery or injections. Of these, [...]

Multaq and Death By Heart Problems

Multaq, also known as Dronedarone, is used to treat heart patients that had atrial fibrillation, which is a rhythm disorder that could make the heart beat fast and irregular. It’s also used to treat atrial flutter, which also causes the heart to beat fast, but is still considered regular. However, this drug is known to [...]

Latest Medical Device Injury News

More Sufferers File Lawsuits Against DePuy Orthopaedics

Two more people who’ve suffered serious injuries blamed on the defective and recalled DePuy Orthopaedics ASR hip implant are the latest to join a growing federal class-action lawsuit against the medical device firm and its parent company, Johnson & Johnson. The plaintiff’s are being represented by the law firm of Parker Waichman LLP and are [...]

Metal-on-Metal Hip Implant Finds No Increased Cancer Risk?

We have written countless articles discussing the dangers of metal-on-metal implants, yet a new study is downplaying the potential dangerous effects, such as the risk of cancer. The recent study was published in the British Medical Journal which analyzed cancer rates among patients with metal-on-metal implants versus patients with other types of implants as well [...]

St. Jude’s Wants Study Retracted Due To Inaccuracy

St. Jude Medical has asked the Heart Rhythm Journal to retract a study published last month that linked its Riata line of internal defibrillator leads to more 20 deaths. In a statement issued by St. Jude, the company asserted the Riata lead study was biased and based on inaccurate facts. According to the Heart Rhythm [...]

Vaginal Mesh Lawsuits Claim Painful Erosion, Organ Damage

An estimated 35,000 women who suffered through bladder control problems brought on by aging, child birth, and a variety of other causes. The lives of those who had adverse reactions to vaginal mesh were literally ruined as many experienced crippling pain and permanent scarring damage from the procedures involved in the insertion and necessary removal of the vaginal mesh.

If you or a loved one suffered vaginal erosion call us immediately at 1-800-810-3457.

FDA Reposts Thoratec HeartMate II LVAS Class I Recall

A recall of Thoratec’s HeartMate II Left Ventricle Assist System (LVAS) that was first announced in February has been designated Class I, the U.S. Food & Drug Administration’s (FDA) most serious type of recall. The HeartMate II LVAS is a heart pump which is used as a bridge to transplantation in heart transplant candidates at [...]